Analysed POLYRIZON LTD (PLRZ:NASDAQ) News Sources
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
13-05-2026
yahoo.com
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
08-06-2026
yahoo.com
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
10-06-2026
yahoo.com
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
29-06-2026
yahoo.com
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
02-07-2026
yahoo.com
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)
02-07-2026
advfn.com
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
02-09-2026
yahoo.com
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
03-09-2026
yahoo.com
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
04-09-2026
yahoo.com
What is the current price of POLYRIZON LTD (PLRZ:NASDAQ)?
The current price of POLYRIZON LTD (PLRZ:NASDAQ) is $9.05.
POLYRIZON LTD (PLRZ:NASDAQ) absolute price change since previous trading day?
The absolute price change of POLYRIZON LTD (PLRZ:NASDAQ) since the previous trading day is $0.0617.
POLYRIZON LTD (PLRZ:NASDAQ) percentage price change since previous trading day?
The percentage price change of POLYRIZON LTD (PLRZ:NASDAQ) since the previous trading day is 0.6864%.
What is the most recent average sentiment score for POLYRIZON LTD (PLRZ:NASDAQ)?
The most recent average sentiment score for POLYRIZON LTD (PLRZ:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for POLYRIZON LTD (PLRZ:NASDAQ)?
The most recent sentiment for POLYRIZON LTD (PLRZ:NASDAQ) is .
SEC-8K** Filing Available For POLYRIZON LTD (PLRZ:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.